

SUPPLEMENT

Risk factors for severe PCR-positive SARS-CoV-2 infection in hospitalized children: a multicenter cohort study

Supplementary Methods

eTable 1. Multivariable logistic regression models focusing only on baseline characteristics as risk factors for severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 clinical progression scale of ≥ 6)

eTable 2. Demographic and clinical characteristics of patients PCR-positive SARS-CoV-2 infection (n=403) according to severity of disease (WHO COVID-19 clinical progression scale of ≥ 6 and/or ICU admission)

eTable 3 Age stratified univariable logistic regression analysis among children aged younger than 12 years (n=308) and adolescents 12 years of age and older (n=93) for severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 clinical progression scale of ≥ 6)

eTable 4. Demographic and clinical characteristics among children aged less than 12 years (n=308) according to according to severity of disease (WHO COVID-19 clinical progression scale of ≥ 6)

eTable 5. Demographic and clinical characteristics among adolescents aged 12 to 17 years (n=93) according severity of disease (WHO COVID-19 clinical progression scale of ≥ 6)

eTable 6. Multivariable logistic regression models for factors associated with severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 progression scale of ≥ 6), stratified according to age groups

eTable 7. Demographic and clinical characteristics among non-MIS-C patients (n=322) with PCR-positive SARS-CoV-2 infection, according to severity of disease (WHO COVID-19 clinical progression scale of ≥ 6)

eTable 8. Multivariable logistic regression models among non-MIS-C patients for factors associated with severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 clinical progression scale of ≥ 6).

Supplementary Methods

Ethics approval was obtained from the following ethics review boards: Comité Ético Científico Hospital Nacional de Niños, San José, Costa Rica (CEC-HNN-030-2020), Iran University of Medical Sciences Ethics Review Committee (IR.IUMS.REC.1399.187), The Hospital for Sick Children Research Ethics Board (#1000070091), Pediatric Panel of the Research Ethics Board of the Research Institute of the McGill University Health Centre (#MP-37-2021-6561), Conjoint Health Research Ethics Board, University of Calgary (REB20-0594), Children's Hospital of Eastern Ontario Research Ethics Board (CHEOREB# 20/32X), University of British Columbia Children's and Women's Research Ethics Board (# H20-00977), Health Research Ethics Board, University of Manitoba (HSC23858), University of Saskatchewan Biomedical Research Ethics Board (Study 1921), Hamilton Integrated Research Ethics Board (ID 11240), Centre Hospitalier Universitaire de Québec-Université Laval (37-2021-6561), and Health Research Ethics Board, University of Alberta (Pro00099426), CHU Sainte-Justine, Université de Montréal (MEO-37-2021-3123), Lawson Health Research Institute (ReDA ID 9857), Trillium Health Partners Research Ethics Board (#1002), Queen's University Health Sciences & Affiliated Teaching Hospitals Research Ethics Board (#6029527), IWK Research Ethics Board (#1026214), Newfoundland and Labrador Health Research Ethics Board (# 2020.047)

Classification of chronic health condition was the following: neurological, cardiac, pulmonary (including asthma), metabolic (including diabetes mellitus), renal, and chromosomal disorders; immunosuppression (including malignancy), obesity, prematurity (<37 weeks gestational age), anemia and/or hemoglobinopathy and 'other' comorbidities which included patients who could not be classified into the previous categories.

eTable 1. Multivariable logistic regression models focusing only on baseline characteristics as risk factors for severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 clinical progression scale of ≥ 6). (n=401)

Model 1 incorporates the number of comorbidities, model 2 selected individual comorbidities

Covariates	Model 1 aOR (95% CI)	Model 2 aOR (95% CI)
Age category		
<1 year	Ref.	Ref.
1-4 years	1.41 (0.71-2.79)	1.45 (0.73-2.86)
5-11 years	1.52 (0.75-3.05)	1.32 (0.65-2.68)
≥ 12 years	2.22 (1.12-4.40)	1.41 (0.66-3.00)
Comorbidities		
None	Ref.	-
1 comorbidity	1.32 (0.76-2.29)	-
Multiple (≥ 2) comorbidities	2.00 (1.09-3.65)	-
Obesity	-	3.42 (1.66-7.06)
Anemia or hemoglobinopathy	-	3.14 (1.00-9.88)
Neurological disorders	-	2.12 (1.13-3.95)

aOR adjusted odds ratio; CI confidence intervals

eTable 2. Demographic and clinical characteristics of patients PCR-positive SARS-CoV-2 infection (n=403) according to severity of disease (WHO COVID-19 clinical progression scale of ≥ 6 and/or ICU admission)

	Mild/Moderate Disease* N=275 (%)	Severe Disease and/or ICU admission* N=128 (%)	p-value**
Demographics			
Median Age in years (IQR) ¹	3.09 (0.30-10.10)	6.04 (1.24-12.67)	0.004
Age ≤ 30 days	30 (81.1%)	7 (18.9%)	0.115
Age category ¹			
<1 year	88 (77.9%)	25 (22.1%)	0.024
1-4 years	74 (69.8%)	32 (30.2%)	
5-11 years	55 (61.8%)	34 (38.2%)	
≥ 12 years	56 (60.2%)	37 (39.8%)	
Male sex	157 (69.2%)	70 (30.8%)	0.730
Admission period			
Prior to July 1, 2020	14 (73.7%)	5 (26.3%)	0.438
July 1, 2020 to Dec 31, 2020	108 (71.5%)	43 (28.5%)	
Jan 1, 2021 to May 31, 2021	153 (65.7%)	80 (34.3%)	
Admitted in Canada	175 (65.8%)	91 (34.2%)	0.174
Number of Comorbidities			
None	157 (72.7%)	59 (27.3%)	0.051
At least 1 comorbidity	118 (63.1%)	69 (36.9%)	
Multiple (≥ 2) comorbidities	42 (56.0%)	33 (44.0%)	0.017
None	157 (72.7%)	59 (27.3%)	0.028
1 comorbidity	76 (67.8%)	36 (32.1%)	
Multiple (≥ 2) comorbidities	42 (56.0%)	33 (44.0%)	
Individual comorbidities²			
Obesity	24 (48.0%)	26 (52.0%)	0.002
Pulmonary disorders	32 (59.2%)	22 (40.7%)	0.172
Non-asthma pulmonary disorders ³	10 (45.4%)	12 (54.5%)	0.034
Asthma	22 (68.7%)	10 (31.2%)	1.0
Prematurity (<37 weeks gestational age)	17 (56.7%)	13 (43.3%)	0.226
Immunosuppression	26 (83.9%)	5 (16.1%)	0.069
Malignancy ⁴	15 (93.7%)	1 (6.2%)	0.027
Anemia or hemoglobinopathy ⁵	7 (53.8%)	6 (43.1%)	0.406
Sickle cell anemia	4 (66.7%)	2 (33.3%)	1.0
Neurological disorders ⁶	30 (53.6%)	26 (46.4%)	0.017
Cardiac disorders	12 (63.1%)	7 (36.8%)	0.814
Metabolic disorders	6 (50.0%)	6 (50.0%)	0.288
Diabetes mellitus	2 (40.0%)	3 (60.0%)	0.332
Renal disorders	7 (50.0%)	7 (50.0%)	0.230
Hypertension	4 (44.4%)	5 (55.5%)	0.150
Chromosomal disorders ⁷	3 (37.5%)	5 (62.5%)	0.116
Other ⁸	13 (52.0%)	12 (48.0%)	0.114
Clinical Features			
Fever prior to or during admission ⁹	207 (68.5%)	95 (31.4%)	0.445

Cough	135 (64.9%)	73 (35.1%)	0.168
Shortness of breath	100 (53.2%)	88 (46.8%)	<0.001
Vomiting	83 (65.3%)	44 (34.6%)	0.466
Rhinitis	90 (72.0%)	35 (28.0%)	0.331
Diarrhea	81 (70.4%)	34 (29.6%)	0.631
Abdominal pain	70 (64.8%)	38 (35.2%)	0.440
Headache	46 (63.9%)	26 (36.1%)	0.462
Rash	45 (65.2%)	24 (34.8%)	0.653
Conjunctivitis	39 (57.3%)	29 (42.6%)	0.049
Myalgia	40 (66.7%)	20 (33.3%)	0.894
Pharyngitis	46 (76.7%)	14 (23.3%)	0.171
Wheeze	34 (63.0%)	20 (37.0%)	0.461
Chest pain	26 (66.7%)	13 (33.3%)	0.967
Cracked lips	22 (57.9%)	16 (42.1%)	0.209
Edema of hands and feet	16 (59.2%)	11 (40.7%)	0.410
Anosmia	8 (66.7%)	4 (33.3%)	1.0
Seizures	5 (45.4%)	6 (54.5%)	0.111
Coinfections			
Bacterial (positive cultures) ¹⁰	13 (54.2%)	11 (45.8%)	0.193
Viral	15 (46.9%)	17 (53.1%)	0.012
Bacterial and/or viral	28 (51.8%)	26 (48.1%)	0.009
Imaging			
No chest imaging performed	86 (94.5%)	5 (5.5%)	<0.001
CXR and/or CT chest normal or had findings unrelated to COVID-19	96 (79.3%)	25 (20.7%)	
CXR and/or CT chest abnormalities compatible with COVID-19	93 (48.7%)	98 (51.3%)	
Laboratory investigations			
Leukopenia (<4 X10 ⁹ /L) ¹¹	44 (74.6%)	15 (25.4%)	0.239
Leukocytosis (>15x10 ⁹ /L) ¹¹	30 (63.8%)	17 (36.2%)	0.731
Neutropenia (<1.5x 10 ⁹ /L) ¹²	68 (80.9%)	16 (19.0%)	<0.001
Normal neutrophil count ¹²	131 (72.0%)	51 (28.0%)	
Neutrophilia ¹²	56 (48.3%)	60 (51.7%)	0.004
Thrombocytopenia (<100 x 10 ⁹ /L) ¹³	22 (52.4%)	20 (47.6%)	
Normal platelet count ¹³	189 (72.4%)	72 (27.6%)	
Thrombocytosis (>450 x 10 ⁹ /L) ¹³	47 (57.3%)	35 (42.7%)	<0.001
CRP not done ¹⁴	49 (81.7%)	11 (18.3%)	
Normal CRP ¹⁴	165 (73.7%)	59 (26.3%)	
CRP >50 (mg/L) ¹⁴	61 (51.3%)	58 (48.7%)	0.160
Ferritin >500 (mcg/L) ¹⁵	24 (43.6%)	31 (56.4%)	
Albumin<29 (g/L) ¹⁶	17 (36.9%)	29 (63.0%)	<0.001
Complications			
MIS-C diagnosis	44 (54.3%)	37 (45.7%)	0.004

CT computed tomography; CRP C-reactive protein; CXR chest x-ray; IQR interquartile range; MIS-C multisystem inflammatory syndrome in children

* Percentages were calculated for the row, i.e., % of a stratum with severe or mild/moderate disease.

** Comparisons performed using chi squared or Fisher's exact test as appropriate for categorical data and Wilcoxon rank sum test for continuous data as appropriate.

- ¹ A total of 2 children with mild/moderate disease are missing date of birth.
- ² Children are listed more than once if they had more than one comorbidity.
- ³ Clinical information is available for 14/22 patients: obstructive sleep apnea (n=5); bronchopulmonary dysplasia (n=3); pulmonary hypertension (n=2); cystic fibrosis (n=1); chronic aspiration pneumonia (n=1); subglottic stenosis (n=1); Pierre-Robin anomaly (n=1)
- ⁴ Malignancy consists of the following: acute lymphoblastic leukemia (n=11); neuroblastoma (n=2); lymphoma (n=1); rhabdomyosarcoma (n=1); and osteosarcoma (n=1)
- ⁵ Anemia and/or hemoglobinopathy consist of the following: sickle cell disease (n=6); Glucose-6-phosphate dehydrogenase deficiency (n=2); anemia of chronic disease (n=2); ovalocytosis (n=1); pancytopenia of unknown etiology (n=1); iron deficient anemia (n=1)
- ⁶ Additional information is available for 47/56 patients: syndromic condition with global developmental delay (GDD) (n=19); autism and/or GDD of unexplained etiology (n=10); cerebral palsy (n=7); muscular dystrophy (n=3); hydrocephalus (n=2); congenital microcephaly (n=2); brain tumor (n=1); focal cortical dysplasia (n=1); encephalopathy (n=1); epilepsy (n=1)
- ⁷ Additional information is available for 7/8 patients: Trisomy 21 (n=3); unbalanced translocation (n=2); Prader-Willi syndrome (n=1); Miller-Dieker syndrome (n=1)
- ⁸ Other consists of the following: gastrostomy (n=12); liver transplantation (n=2); celiac disease (n=1); Crohn's disease (n=1) failure to thrive (n=1); inflammatory bowel disease (n=1); inflammatory bowel disease and Hirschsprung disease (n=1); unclear liver disease (n=1); esophageal atresia (n=1); scoliosis (n=2); liver cirrhosis & cholestasis (n=1); Glanzmann thrombasthenia (n=1)
- ⁹ A total of 35 children were missing data on fever prior to or during admission (19 with mild/moderate disease and 16 with severe disease) resulting in a total N of 368.
- ¹⁰ Children with one of the following are included: blood culture thought to be truly positive and/or positive endotracheal tube cultures treated with antibiotics for presumptive bacterial pneumonia and/or positive bacterial culture from another site treated with antibiotics.
- ¹¹ A total of 17 children were missing leukocyte values (16 with mild/moderate disease and 1 with severe disease) resulting in a total N of 386.
- ¹² A total of 21 children were missing neutrophil values (20 with mild/moderate disease and 1 with severe disease) resulting in a total N of 382. Cut-off values for neutrophilia are age dependent.
- ¹³ A total of 18 children were missing a platelet value (17 with mild/moderate disease and 1 with severe disease) resulting in a total N of 385.
- ¹⁴ A total of 60 children were missing a CRP value (49 with mild/moderate disease and 11 with severe disease) resulting in a total N of 343.
- ¹⁵ The highest ferritin value measured variable used and a total of 220 children were missing a value (179 with mild/moderate disease and 41 with severe disease) resulting in a total N of 183.
- ¹⁶ A total of 271 children were missing albumin values (199 with mild/moderate disease and 72 with severe disease) resulting in a total N of 132.

eTable 3 Age stratified univariable logistic regression analysis among children aged younger than 12 years (n=308) and adolescents 12 years of age and older (n=93) for severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 clinical progression scale of ≥ 6)

	Unadjusted OR among those younger than 12 years of age N=308	Unadjusted OR among those 12 years of age and older N=93
	OR (95% CI)	OR (95% CI)
Number of comorbidities		
None	Ref.	Ref.
1 comorbidity	1.14 (0.58-2.25)	1.78 (0.65-4.87)
Multiple (≥ 2) comorbidities	2.85 (1.45-5.58)	1.22 (0.39-3.86)
Individual comorbidities		
Obesity	3.70 (1.15-11.86)	2.93 (1.22-7.05)
Pulmonary disorders	2.38 (1.17-4.82)	0.69 (0.20-2.40)
Non-asthma pulmonary disorders	4.33 (1.60-11.70)	0.44 (0.05-4.08)
Anemia or hemoglobinopathy	3.03 (0.90-10.26)	1.84 (0.11-30.47)
Neurological disorders	2.74 (1.33-5.63)	1.42 (0.51-3.99)
Cardiac disorders	2.43 (0.83-7.09)	-
Hypertension	3.57 (0.70-18.13)	3.81 (0.33-43.65)
Chromosomal disorders	4.84 (1.06-22.18)	-
Clinical Features		
Fever prior to or during admission	0.86 (0.42-1.77)	4.05 (0.84-19.44)
Shortness of breath	5.98 (3.30-10.86)	3.73 (1.26-11.02)
Conjunctivitis	1.63 (0.85-3.10)	1.61 (0.45-5.73)
Pharyngitis	0.40 (0.13-1.17)	0.52 (0.18-1.47)
Wheeze	1.86 (0.94-3.70)	0.71 (0.13-3.88)
Seizures	2.88 (0.75-11.03)	1.84 (0.11-30.47)
Coinfections		
Bacterial and/or viral	4.11 (2.10-8.02)	1.24 (0.32-4.76)
Imaging		
CXR and/or CT normal or had findings unrelated to COVID-19	Ref.	Ref.
No chest imaging done	0.07 (0.01-0.52)	0.54 (0.04-6.77)
CXR or CT abnormalities compatible with COVID-19	3.57 (1.90-6.70)	5.57 (1.16-26.69)
Laboratory investigations		
Neutropenia ($<1.5 \times 10^9/L$)	0.72 (0.32-1.66)	1.38 (0.42-4.52)
Normal neutrophil count	Ref.	Ref.
Neutrophilia	3.02 (1.64-5.58)	3.23 (1.17-8.94)
Thrombocytopenia ($<100 \times 10^9/L$)	1.79 (0.78-4.07)	1.10 (0.24-5.01)
Normal platelet count	Ref.	Ref.
Thrombocytosis ($>450 \times 10^9/L$)	1.66 (0.89-3.09)	2.30 (0.56-9.35)
CRP not done	Ref.	Ref.
Normal CRP	1.18 (0.53-2.65)	-
CRP >50 (mg/L)	2.04 (0.86-4.84)	-
Complications		
MIS-C	1.52 (0.81-2.85)	1.60 (0.56-4.55)

Note. Among those less than 12 years of age, N for model with fever is 281 as 27 deleted due to missingness, N for models with neutrophil counts are 292 as 16 deleted due to missingness, N for models with platelet counts

are 295 as 13 deleted due to missingness. Among those 12 years of age and older, N for model with fever is 86 as 7 deleted due to missingness, N for models with neutrophil counts and platelet counts are 88 as 5 deleted due to missingness.

OR odds ratio; CT computed tomography; CRP C-reactive protein; CXR chest x-ray; IQR interquartile range; MIS-C multisystem inflammatory syndrome in children

eTable 4. Demographic and clinical characteristics among children aged less than 12 years (n=308) according to severity of disease (WHO COVID-19 clinical progression scale of ≥ 6)

	Mild/Moderate Disease* N=239 (%)	Severe Disease* N=69 (%)	p-value**
Demographics			
Male sex	136 (76.8%)	41 (23.2%)	0.815
Admission period			
Prior to July 1, 2020	13 (81.2%)	3 (18.7%)	0.973
Between July 1, 2020 to Dec 31, 2020	97 (78.2%)	27 (21.8%)	
Between Jan 1, 2021 to May 31, 2021	129 (76.8%)	39 (23.2%)	
Admitted in Canada	138 (77.5%)	40 (22.5%)	1.0
Number of Comorbidities			
None	150 (81.5%)	34 (18.5%)	0.061
At least 1 comorbidity	89 (71.8%)	35 (28.2%)	
Multiple (≥ 2) comorbidities	31 (60.8%)	20 (39.2%)	0.001
None	150 (81.5%)	34 (18.5%)	0.007
1 comorbidity	58 (79.4%)	15 (20.5%)	
Multiple (≥ 2) comorbidities	31 (60.8%)	20 (39.2%)	
Individual comorbidities¹			
Obesity	6 (50.0%)	6 (50.0%)	0.047
Pulmonary disorders	25 (62.5%)	15 (37.5%)	0.024
Non-asthma pulmonary disorders	8 (47.0%)	9 (52.9%)	0.005
Asthma	17 (73.9%)	6 (26.1%)	0.857
Prematurity (<37 weeks gestational age)	20 (71.4%)	8 (28.6%)	0.560
Immunosuppression	18 (81.8%)	4 (18.2%)	0.793
Cancer	12 (92.3%)	1 (7.7%)	0.310
Anemia or hemoglobinopathy	6 (54.5%)	5 (45.4%)	0.073
Sickle cell anemia	3 (75.0%)	1 (25.0%)	1.0
Neurological disorders	22 (59.4%)	15 (40.5%)	0.009
Cardiac disorders	9 (60.0%)	6 (40.0%)	0.174
Metabolic disorders	5 (83.3%)	1 (16.7%)	1.0
Diabetes mellitus	1 (100.0%)	0	1.0
Renal disorders	7 (58.3%)	5 (41.7%)	0.201
Hypertension	3 (50.0%)	3 (50.0%)	0.128
Chromosomal disorders	3 (42.8%)	4 (57.1%)	0.047
Other	11 (64.7%)	6 (35.3%)	0.311
Clinical Features			
Fever prior to or during admission ²	182 (79.5%)	47 (20.5%)	0.826
Cough	104 (75.4%)	34 (24.6%)	0.478
Shortness of breath	73 (59.3%)	50 (40.6%)	<0.001
Vomiting	67 (72.8%)	25 (27.2%)	0.245
Rhinitis	84 (77.8%)	24 (22.2%)	1.0
Diarrhea	64 (77.1%)	19 (22.9%)	1.0
Abdominal pain	61 (76.2%)	19 (23.7%)	0.857
Headache	33 (75.0%)	11 (25.0%)	0.802

Rash	44 (74.6%)	15 (25.4%)	0.656
Conjunctivitis	40 (70.2%)	17 (29.8%)	0.189
Myalgia	31 (79.5%)	8 (20.5%)	0.922
Pharyngitis	32 (88.9%)	4 (11.1%)	0.092
Wheeze	31 (67.4%)	15 (32.6%)	0.108
Chest pain	11 (73.3%)	4 (26.7%)	0.751
Cracked lips	24 (72.7%)	9 (27.3%)	0.625
Edema of hands and feet	16 (72.7%)	6 (27.3%)	0.762
Anosmia	4 (100.0%)	0	0.578
Seizures	5 (55.5%)	4 (44.4%)	0.117
Coinfections			
Bacterial (positive cultures) ³	10 (55.5%)	8 (44.4%)	0.043
Viral	13 (46.4%)	15 (53.6%)	<0.001
Bacterial and/or viral	23 (52.3%)	21 (47.7%)	<0.001
Imaging			
No chest imaging done	77 (98.7%)	1 (1.3%)	<0.001
CXR and/or CT chest normal or had findings unrelated to COVID-19	88 (83.8%)	17 (16.2%)	
CXR and/or CT chest abnormalities compatible with COVID-19	74 (59.2%)	51 (40.8%)	
Laboratory investigations			
Leukopenia (<4 X10 ⁹ /L) ⁴	33 (91.7%)	3 (8.3%)	0.033
Leukocytosis (>15x10 ⁹ /L) ⁴	30 (71.4%)	12 (28.6%)	0.472
Neutropenia (<1.5x 10 ⁹ /L) ⁵	58 (86.6%)	9 (13.4%)	<0.001
Normal neutrophil count ⁵	112 (82.3%)	24 (17.6%)	
Neutrophilia ⁵	54 (60.7%)	35 (39.3%)	
Thrombocytopenia (<100 x 10 ⁹ /L) ⁶	23 (69.7%)	10 (30.3%)	0.164
Normal platelet count ⁶	152 (80.4 %)	37 (19.6%)	
Thrombocytosis (>450 x 10 ⁹ /L) ⁶	52 (71.2%)	21 (28.8%)	
CRP not done ⁷	42 (82.3%)	9 (17.6%)	0.133
Normal CRP ⁷	142 (79.8%)	36 (20.2%)	
CRP >50 (mg/L) ⁷	55 (69.6%)	24 (30.4%)	
Ferritin >500 (mcg/L) ⁸	24 (63.1%)	14 (36.8%)	0.523
Albumin<29 (g/L) ⁹	21 (56.7%)	16 (43.2%)	0.033
Complications			
MIS-C diagnosis	45 (71.4%)	18 (28.6%)	0.251

CT computed tomography; CRP C-reactive protein; CXR chest x-ray; MIS-C multisystem inflammatory syndrome in children

* Percentages were calculated for the row, i.e., % of a stratum with severe or mild/moderate disease.

** Comparisons performed using chi squared or Fisher's exact test as appropriate for categorical data.

¹ Children are listed more than once if they had more than one comorbidity.

² A total of 27 children were missing data on fever prior to or during admission (17 with mild/moderate disease and 10 with severe disease) resulting in a total N of 281.

³ Children with one of the following are included: blood culture thought to be truly positive and/or positive endotracheal tube cultures treated with antibiotics for presumptive bacterial pneumonia and/or positive bacterial culture from another site treated with antibiotics.

⁴ A total of 13 children were missing leukocyte values (12 with mild/moderate disease and 1 with severe disease) resulting in a total N of 295.

⁵ A total of 16 children were missing neutrophil values (15 with mild/moderate disease and 1 with severe disease) resulting in a total N of 292. Cut-off values for neutrophilia are age dependent

⁶ A total of 13 children were missing platelet values (12 with mild/moderate disease and 1 with severe disease) resulting in a total N of 295.

⁷ A total of 51 children were missing a CRP value (42 with mild/moderate disease and 9 with severe disease) resulting in a total N of 257.

⁸ The highest ferritin value measured variable used and a total of 181 children were missing a value (152 with mild/moderate disease and 29 with severe disease) resulting in a total N of 127.

⁹ A total of 205 children were missing albumin values (166 with mild/moderate disease and 39 with severe disease) resulting in a total N of 103.

eTable 5. Demographic and clinical characteristics among adolescents aged 12 to 17 years (n=93) according severity of disease (WHO COVID-19 clinical progression scale of ≥ 6)

	Mild/Moderate Disease* N=60 (%)	Severe Disease* N=33 (%)	p-value**
Demographics			
Male sex	34 (69.4%)	15 (30.6%)	0.413
Admission period			
Prior to July 1, 2020	3 (100.0%)	0	0.112
Between July 1, 2020 to Dec 31, 2020	20 (76.9%)	6 (23.1%)	
Between Jan 1, 2021 to May 31, 2021	37 (57.8%)	27 (42.2%)	
Admitted in Canada	56 (64.4%)	31 (35.6%)	1.0
Number of comorbidities			
None	22 (71.0%)	9 (29.0%)	0.490
At least 1 comorbidity	38 (61.3%)	24 (38.7%)	
Multiple (≥ 2) comorbidities	16 (66.7%)	8 (33.3%)	0.994
None	22 (71.0%)	9 (29.0%)	0.512
1 comorbidity	22 (57.9%)	16 (42.1%)	
Multiple (≥ 2) comorbidities	16 (66.7%)	8 (33.3%)	
Individual comorbidities¹			
Obesity	19 (50.0%)	19 (50.0%)	0.027
Pulmonary disorders	10 (71.4%)	4 (28.6%)	0.763
Non-asthma pulmonary disorders	4 (80.0%)	1 (20.0%)	0.652
Asthma	6 (66.7%)	3 (33.3%)	1.0
Prematurity (<37 weeks gestational age)	0	2 (100.0%)	0.123
Immunosuppression	7 (87.5%)	1 (12.5%)	0.252
Cancer	2 (100.0%)	0	0.537
Anemia or hemoglobinopathy	1 (50.0%)	1 (50.0%)	1.0
Sickle cell anemia	1 (50.0%)	1 (50.0%)	1.0
Neurological disorders	11 (57.9%)	8 (42.1%)	0.684
Cardiac disorders	4 (100.0%)	0	0.293
Metabolic disorders	3 (50.0%)	3 (50.0%)	0.662
Diabetes mellitus	2 (50.0%)	2 (50.0%)	0.613
Renal disorders	2 (100.0%)	0	0.537
Hypertension	1 (33.3%)	2 (66.7%)	0.286
Chromosomal disorders	0	1 (100.0%)	0.355
Other	6 (75.0%)	2 (25.0%)	0.707
Clinical Features			
Fever prior to or during admission ²	43 (59.7%)	29 (40.3%)	0.075
Cough	41 (60.3%)	27 (39.7%)	0.246
Shortness of breath	36 (56.2%)	28 (43.7%)	0.019
Vomiting	23 (67.6%)	11 (32.3%)	0.799
Rhinitis	12 (75.0%)	4 (25.0%)	0.401
Diarrhea	23 (71.9%)	9 (28.1%)	0.397
Abdominal pain	19 (67.8%)	9 (32.1%)	0.837
Headache	19 (67.8%)	9 (32.1%)	0.837
Rash	6 (60.0%)	4 (40.0%)	0.739
Conjunctivitis	6 (54.5%)	5 (45.4%)	0.512

Myalgia	15 (71.4%)	6 (28.6%)	0.622
Pharyngitis	18 (75.0%)	6 (25.0%)	0.318
Wheeze	5 (71.4%)	2 (28.6%)	1.0
Chest pain	16 (66.7%)	8 (33.3%)	0.994
Cracked lips	2 (40.0%)	3 (60.0%)	0.343
Edema of hands and feet	3 (60.0%)	2 (40.0%)	1.0
Anosmia	6 (75.0%)	2 (25.0%)	0.707
Seizures	1 (50.0%)	1 (50.0%)	1.0
Coinfections			
Bacterial (positive cultures) ³	4 (66.7%)	2 (33.3%)	1.0
Viral	2 (50.0%)	2 (50.0%)	0.613
Bacterial and/or viral	6 (60.0%)	4 (40.0%)	0.739
Imaging			
No chest imaging done	12 (92.3%)	1 (7.7%)	0.0039
CXR and/or CT chest normal or had findings unrelated to COVID-19	13 (86.7%)	2 (13.3%)	
CXR and/or CT chest abnormalities compatible with COVID-19	35 (53.8%)	30 (46.1%)	
Laboratory investigations			
Leukopenia (<4 X10 ⁹ /L) ⁴	14 (60.9%)	9 (39.1%)	1.0
Leukocytosis (>15x10 ⁹ /L) ⁴	1 (33.3%)	2 (66.7%)	0.552
Neutropenia (<1.5x 10 ⁹ /L) ⁵	11 (64.7%)	6 (35.3%)	0.068
Normal neutrophil count ⁵	33 (71.7%)	13 (28.3%)	
Neutrophilia ⁵	11 (44.0%)	14 (56.0%)	
Thrombocytopenia (<100 x 10 ⁹ /L) ⁶	5 (62.5%)	3 (37.5%)	0.505
Normal platelet count ⁶	46 (64.8%)	25 (35.2%)	
Thrombocytosis (>450 x 10 ⁹ /L) ⁶	4 (44.4%)	5 (55.5%)	
CRP not done ⁷	9 (100.0%)	0	0.0147
Normal CRP ⁷	30 (68.2%)	14 (31.8%)	
CRP >50 (mg/L) ⁷	21 (52.5%)	19 (47.5%)	
Ferritin >500 (mcg/L) ⁸	6 (35.3%)	11 (64.7%)	0.281
Albumin<29 (g/L) ⁹	3 (33.3%)	6 (66.7%)	0.106
Complications			
MIS-C diagnosis	10 (55.5%)	8 (44.4%)	0.541

CT computed tomography; CRP C-reactive protein; CXR chest x-ray; MIS-C multisystem inflammatory syndrome in children; PCR polymerase chain reaction; WHO World Health Organization.

* Percentages were calculated for the row, i.e., % of a stratum with severe or mild/moderate disease.

** Comparisons performed using chi squared or Fisher's exact test as appropriate for categorical data.

¹ Children are listed more than once if they had more than one comorbidity.

² A total of 7 children were missing data on fever prior to or during admission (5 with mild/moderate disease and 2 with severe disease) resulting in a total N of 86.

³ Children with one of the following are included: blood culture thought to be truly positive and/or positive endotracheal tube cultures treated with antibiotics for presumptive bacterial pneumonia and/or positive bacterial culture from another site treated with antibiotics.

⁴ A total of 4 children were missing leukocyte values (4 with mild/moderate disease) resulting in a total N of 89.

⁵ A total of 5 children were missing neutrophil values (5 with mild/moderate disease) resulting in a total N of 88. Cut-off values for neutrophilia are age dependent

⁶ A total of 5 children were missing platelet values (5 with mild/moderate disease) resulting in a total N of 88.

⁷ A total of 9 children were missing a CRP value (9 with mild/moderate disease) resulting in a total N of 84.

⁸ The highest ferritin value measured variable used and a total of 38 children were missing a value (33 with mild/moderate disease and 5 with severe disease) resulting in a total N of 55.

⁹ A total of 64 children were missing albumin values (43 with mild/moderate disease and 21 with severe disease) resulting in a total N of 29.

eTable 6. Multivariable logistic regression models for factors associated with severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 progression scale of ≥ 6), stratified according to age groups.

Model 1 incorporates selected individual comorbidities, model 2 the number of comorbidities while excluding individual comorbidities; both in children <12 years of age.

Model 3 is incorporates selected individual comorbidities in adolescents ≥ 12 years

Covariates	Model 1: Children < 12 years old aOR (95% CI)	Model 2: Children < 12 years old aOR (95% CI)	Model 3: Children ≥ 12 years old aOR (95% CI)
Number of comorbidities			
None	-	Ref.	-
1 comorbidity	-	1.57 (0.69-3.60)	-
Multiple (>2) comorbidities	-	2.60 (1.12-6.06)	-
Individual comorbidities			
Obesity	1.17 (0.29-4.67)	-	3.21 (1.15-8.93)
Non-asthma pulmonary disorders	1.68 (-0.45-6.22)	-	-
Anemia or hemoglobinopathy	-	-	-
Neurological disorders	3.16 (1.19-8.43)	-	-
Cardiac disorders	-	-	-
Hypertension	-	-	-
Chromosomal disorders	-	-	-
Coinfections			
Bacterial and/or viral	2.60 (1.13-5.99)	2.50 (1.10-5.69)	-
Imaging			
No chest imaging done	0.15 (0.02-1.24)	0.16 (0.02-1.28)	0.82 (0.05-8.93)
CXR and/or CT normal or had findings unrelated to COVID-19	Ref.	Ref.	Ref.
CXR or CT abnormalities compatible with COVID-19	3.10 (1.49-6.42)	2.99 (1.45-6.18)	7.87 (1.32-46.97)
Clinical presentation			
Shortness of breath	5.02 (2.10-12.04)	5.03 (2.12-11.88)	-
Complications			
MIS-C diagnosis	4.85 (1.70-13.83)	4.92 (1.72-14.04)	1.11 (0.27-4.67)
Laboratory investigations			
Neutrophilia	1.54 (0.74-3.22)	1.55 (0.75-3.22)	5.81 (1.85-18.22)

aOR adjusted odds ratio; CI confidence interval; CT computed tomography; CXR chest x-ray; MIS-C multisystem inflammatory syndrome in children

eTable 7. Demographic and clinical characteristics among non-MIS-C patients (n=322) with PCR-positive SARS-CoV-2 infection, according to severity of disease (WHO COVID-19 clinical progression scale of ≥ 6)

	Mild/Moderate Disease* N=246 (%)	Severe Disease* N=76 (%)	P-value**	Unadjusted OR for severe disease
Demographics				
Median Age in years (IQR) ¹	2.08 (0.23-9.66)	3.65 (0.98-14.41)	0.0062	1.04 (1.00-1.09)
Age ≤ 30 days	34 (91.9%)	3 (8.1%)	0.0218	0.26 (0.08-0.86)
Age category ¹				
<1 year	94 (83.2%)	19 (16.8%)	0.0303	Ref.
1-4 years	61 (71.8%)	24 (28.2%)		1.95 (0.98-3.85)
5-11 years	39 (83.0%)	8 (17.0%)		1.01 (0.41-2.51)
≥ 12 years	50 (66.7%)	25 (33.3%)		2.47 (1.24-4.92)
Male sex	137 (76.5%)	42 (23.5%)	1.0	0.98 (0.58-1.65)
Admission period				
Prior to July 1, 2020	15 (88.2%)	2 (11.8%)	0.280	Ref.
Between July 1, 2020 to Dec 31, 2020	93 (79.5%)	24 (20.5%)		1.93 (0.41-9.05)
Between Jan 1, 2021 to May 31, 2021	138 (73.4%)	50 (26.6%)		2.72 (0.60-12.31)
Admitted in Canada	158 (76.3%)	49 (23.7%)	1.0	1.01 (0.59-1.73)
Number of comorbidities				
None	128 (83.7%)	25 (16.3%)	0.0053	Ref.
At least 1 comorbidity	118 (69.8%)	51 (30.2%)		2.21 (1.29-3.80)
Multiple (≥ 2) comorbidities	44 (63.8%)	25 (36.2%)		2.25 (1.26-4.01)
None	128 (83.7%)	25 (16.3%)	0.0043	Ref.
1 comorbidity	74 (74.0%)	26 (26.0%)		1.80 (0.97-3.34)
Multiple (≥ 2) comorbidities	44 (63.8%)	25 (36.2%)		2.91 (1.52-5.58)
Individual comorbidities²				
Obesity	24 (55.8%)	19 (44.2%)	0.0013	3.08 (1.58-6.02)
Pulmonary disorders	32 (64.0%)	18 (36.0%)	0.0389	2.07 (1.09-3.96)
Non-asthma pulmonary disorders	12 (54.5%)	10 (45.4%)	0.0250	2.95 (1.22-7.14)
Asthma	20 (71.4%)	8 (28.6%)	0.678	1.33 (0.56-3.15)
Prematurity (<37 weeks gestational age)	19 (65.5%)	10 (34.5%)	0.223	1.81 (0.80-4.08)
Immunosuppression	24 (85.7%)	4 (14.3%)	0.350	0.51 (0.17-1.53)
Cancer	13 (92.8%)	1 (7.1%)	0.201	0.24 (0.03-1.86)
Anemia or hemoglobinopathy	7 (63.6%)	4 (36.4%)	0.295	1.90 (0.54-6.66)
Sickle cell anemia	4 (80.0%)	1 (20.0%)	1.0	0.81 (0.09-7.33)
Neurological disorders	29 (56.9%)	22 (43.1%)	<0.001	3.05 (1.62-5.72)
Cardiac disorders	13 (68.4%)	6 (31.6%)	0.572	1.54 (0.56-4.19)
Metabolic disorders	8 (72.7%)	3 (27.3%)	0.725	1.22 (0.32-4.73)
Diabetes mellitus	3 (75.0%)	1 (25.0%)	1.0	1.08 (0.11-10.54)
Renal disorders	9 (69.2%)	4 (30.8%)	0.514	1.46 (0.44-4.89)
Hypertension	4 (50.0%)	4 (50.0%)	0.093	3.36 (0.82-13.78)

Chromosomal disorders	2 (28.6%)	5 (71.4%)	0.0092	8.59 (1.63-45.23)
Other	15 (65.2%)	8 (34.8%)	0.291	1.81 (0.74-4.45)
Clinical Features				
Fever prior to or during admission ³	172 (77.5%)	50 (22.5%)	0.955	1.08 (0.55-2.11)
Cough	132 (71.7%)	52 (28.3%)	0.0323	1.87 (1.08-3.23)
Shortness of breath	105 (61.0%)	67 (38.9%)	<0.001	10.00 (4.77-20.96)
Vomiting	56 (80.0%)	14 (20.0%)	0.520	0.77 (0.40-1.47)
Rhinitis	85 (78.0%)	24 (22.0%)	0.734	0.87 (0.50-1.51)
Diarrhea	57 (82.6%)	12 (17.4%)	0.226	0.62 (0.31-1.23)
Abdominal pain	35 (81.4%)	8 (18.6%)	0.525	0.71 (0.31-1.60)
Headache	26 (78.8%)	7 (21.2%)	0.900	0.86 (0.36-2.06)
Rash	15 (78.9%)	4 (21.0%)	1.0	0.85 (0.27-2.66)
Conjunctivitis	7 (87.5%)	1 (12.5%)	0.686	0.45 (0.05-3.76)
Myalgia	30 (76.9%)	9 (23.1%)	1.0	0.97 (0.44-2.14)
Pharyngitis	32 (88.9%)	4 (11.1%)	0.063	0.37 (0.13-1.09)
Wheeze	36 (69.2%)	16 (30.8%)	0.250	1.55 (0.81-2.99)
Chest pain	26 (81.2%)	6 (18.7%)	0.644	0.72 (0.29-1.83)
Cracked lips	2 (66.7%)	1 (33.3%)	0.555	1.63 (0.14-18.19)
Edema of hands and feet	1 (50.0%)	1 (50.0%)	0.417	3.27 (0.20-52.86)
Anosmia	7 (87.5%)	1 (12.5%)	0.686	0.45 (0.05-3.76)
Seizures	6 (54.5%)	5 (45.4%)	0.139	2.82 (0.83-9.50)
Coinfections				
Bacterial (positive cultures) ⁴	10 (52.6%)	9 (47.4%)	0.0253	3.17 (1.24-8.12)
Viral	13 (46.4%)	15 (53.6%)	<0.001	4.41 (1.99-9.75)
Bacterial and/or viral	23 (51.1%)	22 (48.9%)	<0.001	3.95 (2.05-7.61)
Imaging				
No chest imaging done	72 (97.3%)	2 (2.7%)	<0.001	Ref.
CXR and/or CT chest normal or had findings unrelated to COVID-19	78 (85.7%)	13 (14.3%)		0.17 (0.04-0.76)
CXR and/or CT chest abnormalities compatible with COVID-19	96 (61.1%)	61 (38.8%)		3.81 (1.95-7.44)
Laboratory investigations				
Leukopenia (<4 X10 ⁹ /L) ⁵	42 (77.8%)	12 (22.2%)	0.798	0.86 (0.42-1.73)
Leukocytosis (>15x10 ⁹ /L) ⁵	31 (77.5%)	9 (22.5%)	0.905	0.88 (0.40-1.94)
Neutropenia (<1.5x 10 ⁹ /L) ⁶	64 (81.0%)	15 (19.0%)	0.0055	0.85 (0.43-1.68)
Normal neutrophil count ⁶	124 (78.5%)	34 (21.5%)		Ref.
Neutrophilia ⁶	39 (60.0%)	26 (40.0%)		2.43 (1.30-4.54)
Thrombocytopenia (<100 x 10 ⁹ /L) ⁷	19 (73.1%)	7 (26.9%)	0.291	1.27 (0.51-3.19)
Normal platelet count ⁷	176 (77.5%)	51 (22.5%)		Ref.
Thrombocytosis (>450 x 10 ⁹ /L) ⁷	35 (67.3%)	17 (32.7%)		1.68 (0.87-3.24)
CRP not done ⁸	51 (86.4%)	8 (13.5%)	0.0033	Ref.
Normal CRP ⁸	168 (77.4%)	49 (22.6%)		1.86 (0.83-4.18)
CRP >50 (mg/L) ⁸	27 (58.7%)	19 (41.3%)		4.49 (1.74-11.58)

Ferritin >500 (mcg/L) ⁹	10 (52.6%)	9 (47.4%)	0.697	1.39 (0.51-3.78)
Albumin <29 (g/L) ¹⁰	4 (36.4%)	7 (63.6%)	0.0345	4.53 (1.17-17.47)

OR, odds ratio; CT computed tomography; CRP C-reactive protein; CXR chest x-ray; IQR interquartile range; MIS-C multisystem inflammatory syndrome in children; PCR polymerase chain reaction; WHO World Health Organization.

* Percentages were calculated for the row, i.e., % of a stratum with severe or mild/moderate disease.

** Comparisons performed using chi squared or Fisher's exact test as appropriate for categorical data and Wilcoxon rank sum test for continuous data as appropriate.

¹ A total of 2 children with mild/moderate disease are missing date of birth.

² Children are listed more than once if they had more than one comorbidity.

³ A total of 34 children were missing data on fever prior to or during admission (22 with mild/moderate disease and 12 with severe disease) resulting in a total N of 288.

⁴ Children with one of the following are included: blood culture thought to be truly positive and/or positive endotracheal tube cultures treated with antibiotics for presumptive bacterial pneumonia and/or positive bacterial culture from another site treated with antibiotics.

⁵ A total of 16 children were missing leukocyte values (15 with mild/moderate disease and 1 with severe disease) resulting in a total N of 306.

⁵ A total of 20 children were missing neutrophil values (19 with mild/moderate disease and 1 with severe disease) resulting in a total N of 302. Cut-off values for neutrophilia are age dependent.

⁷ A total of 17 children were missing platelet values (16 with mild/moderate disease and 1 with severe disease) resulting in a total N of 305.

⁸ A total of 59 children were missing a CRP value (51 with mild/moderate disease and 8 with severe disease) resulting in a total N of 263.

⁹ The highest ferritin value measured variable used and a total of 219 children were missing a value (185 with mild/moderate disease and 34 with severe disease) resulting in a total N of 103.

¹⁰ A total of 250 children were missing albumin values (198 with mild/moderate disease and 52 with severe disease) resulting in a total N of 72.

eTable 8. Multivariable logistic regression models among non-MIS-C patients for factors associated with severe PCR-positive SARS-CoV-2 infection (WHO COVID-19 clinical progression scale of ≥ 6).

Model 1 incorporates the number of comorbidities, model 2 selected individual comorbidities.

Covariates	Model 1 aOR (95% CI)	Model 2 aOR (95% CI)
Age category		
<1 year	Ref.	Ref.
1-4 years	1.00 (0.41-2.47)	1.04 (0.43-2.52)
5-11 years	0.36 (0.11-1.18)	0.31 (0.09-1.08)
≥ 12 years	0.86 (0.35-2.14)	0.62 (0.23-1.70)
Number of comorbidities		
None	Ref.	-
1 comorbidity	2.04 (0.92-4.54)	-
Multiple (≥ 2) comorbidities	2.72 (1.16-6.39)	-
Individual comorbidities		
Obesity	-	2.67 (1.00-7.15)
Neurological disorder	-	4.39 (1.88-10.28)
Coinfections		
Bacterial and/or viral	2.56 (1.17-5.59)	2.84 (1.28-6.30)
Imaging		
No chest imaging done	0.47 (0.09-2.36)	0.43 (0.08-2.22)
CXR and/or CT normal or had findings unrelated to COVID-19	Ref.	Ref.
CXR or CT abnormalities compatible with COVID-19	3.05 (1.38-6.71)	3.03 (1.36-6.77)
Clinical presentation		
Shortness of breath	5.17 (2.28-11.69)	4.92 (2.12-11.41)
Laboratory investigations		
Neutrophilia	1.89 (0.91-3.92)	1.98 (0.94-4.20)

aOR adjusted odds ratio; CI confidence interval; CRP C-reactive protein; CT computed tomography; CXR chest x-ray